Overview Dividends

(TRDA) Entrada Therapeutics - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US29384C1080

RNA, Protein, Neuromuscular, Ocular, EEV

Biotechnology
Market Cap in USD: 404m
IPO / Inception: 2021-10-29
Return 12m vs S&P 500: -50.2%

EPS (Earnings per Share)

EPS (Earnings per Share) of TRDA over the last years for every Quarter: "2020-12": -7.0819, "2021-03": -7.0819, "2021-06": -0.45, "2021-09": -9.78, "2021-12": -0.89, "2022-03": -0.69, "2022-06": -0.74, "2022-09": -0.8, "2022-12": -0.79, "2023-03": -0.21, "2023-06": -0.78, "2023-09": 1.02, "2023-12": -0.29, "2024-03": 0.68, "2024-06": 1.5499, "2024-09": -0.35, "2024-12": 0.03, "2025-03": -0.42, "2025-06": -1.04, "2025-09": -1.06,
EPS CAGR: -26.89%
EPS Trend: 18.3%
Last SUE: -0.09
Qual. Beats: 0

Revenue

Revenue of TRDA over the last years for every Quarter: 2020-12: 0, 2021-03: 0, 2021-06: 0, 2021-09: 0, 2021-12: 0, 2022-03: 0, 2022-06: 0, 2022-09: 0, 2022-12: 0, 2023-03: 25.26, 2023-06: 18.17, 2023-09: 43.735, 2023-12: 41.848, 2024-03: 59.12, 2024-06: 94.694, 2024-09: 19.57, 2024-12: 37.398, 2025-03: 20.558, 2025-06: 1.95, 2025-09: 1.614,
Rev. CAGR: 17.92%
Rev. Trend: 52.0%
Last SUE: -0.37
Qual. Beats: 0

Dividends

Currently no dividends paid
Risk via 5d forecast
Volatility 59.3%
Value at Risk 5%th 95.1%
Relative Tail Risk -2.45%
Reward TTM
Sharpe Ratio -0.65
Alpha -58.66
CAGR/Max DD -0.11
Character TTM
Hurst Exponent 0.449
Beta 1.102
Beta Downside 1.173
Drawdowns 3y
Max DD 76.75%
Mean DD 30.67%
Median DD 21.99%

Description: TRDA Entrada Therapeutics October 28, 2025

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotech that has built a proprietary Endosomal Escape Vehicle (EEV) platform to ferry RNA- and protein-based drugs across cell membranes, targeting intracellular disease drivers that traditional biologics cannot reach. The firm is leveraging this modular delivery system to develop pipelines for neuromuscular and ocular indications, positioning itself as a potential first-in-class player in hard-to-treat intracellular targets.

Recent public filings show the company held roughly $38 million of cash and short-term investments as of Q2 2024, implying a runway of about 12 months at its current burn rate (± 3 months depending on future financing). The global market for neuromuscular-disease therapeutics is projected to surpass $10 billion by 2030, buoyed by an aging demographic and rapid advances in gene-editing technologies. Moreover, biotech R&D spend grew ~9 % year-over-year in 2023, a macro trend that tends to lift valuations for firms offering novel delivery mechanisms like Entrada’s EEV platform.

For a deeper dive into Entrada’s valuation metrics and how its platform compares with peers, you may find ValueRay’s analyst notes a useful next step.

Piotroski VR‑10 (Strict, 0-10) 0.0

Net Income (-103.5m TTM) > 0 and > 6% of Revenue (6% = 3.69m TTM)
FCFTA -0.31 (>2.0%) and ΔFCFTA -28.29pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 510.8% (prev 183.4%; Δ 327.4pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA -0.31 (>3.0%) and CFO -127.9m <= Net Income -103.5m (YES >=105%, WARN >=100%)
NO Net Debt/EBITDA fails (EBITDA <= 0)
Current Ratio 14.08 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (41.5m) change vs 12m ago 2.05% (target <= -2.0% for YES)
Gross Margin 34.24% (prev 98.39%; Δ -64.14pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 12.72% (prev 38.81%; Δ -26.09pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio -8.74 (EBITDA TTM -113.8m / Interest Expense TTM -13.5m) >= 6 (WARN >= 3)

Altman Z'' -1.89

(A) 0.76 = (Total Current Assets 338.3m - Total Current Liabilities 24.0m) / Total Assets 412.9m
(B) -0.57 = Retained Earnings (Balance) -233.9m / Total Assets 412.9m
(C) -0.24 = EBIT TTM -118.0m / Avg Total Assets 483.7m
(D) -3.23 = Book Value of Equity -233.3m / Total Liabilities 72.2m
Total Rating: -1.89 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 39.70

1. Piotroski 0.0pt
2. FCF Yield data missing
3. FCF Margin data missing
4. Debt/Equity 0.15
5. Debt/Ebitda 0.36
6. ROIC - WACC (= -40.50)%
7. RoE -26.42%
8. Rev. Trend 51.97%
9. EPS Trend 18.34%

What is the price of TRDA shares?

As of December 30, 2025, the stock is trading at USD 10.23 with a total of 202,217 shares traded.
Over the past week, the price has changed by -3.67%, over one month by +3.23%, over three months by +75.17% and over the past year by -41.11%.

Is TRDA a buy, sell or hold?

Entrada Therapeutics has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy TRDA.
  • Strong Buy: 2
  • Buy: 2
  • Hold: 0
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the TRDA price?

Issuer Target Up/Down from current
Wallstreet Target Price 16.5 61.3%
Analysts Target Price 16.5 61.3%
ValueRay Target Price 10.9 6.5%

TRDA Fundamental Data Overview December 27, 2025

Market Cap USD = 404.4m (404.4m USD * 1.0 USD.USD)
P/E Forward = 3333.3333
P/S = 6.5728
P/B = 1.1868
Beta = -0.124
Revenue TTM = 61.5m USD
EBIT TTM = -118.0m USD
EBITDA TTM = -113.8m USD
Long Term Debt = 52.4m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 4.35m USD (from shortTermDebt, last quarter)
Debt = 52.4m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -40.9m USD (from netDebt column, last quarter)
Enterprise Value = 129.9m USD (404.4m + Debt 52.4m - CCE 326.8m)
Interest Coverage Ratio = -8.74 (Ebit TTM -118.0m / Interest Expense TTM -13.5m)
FCF Yield = -99.90% (FCF TTM -129.8m / Enterprise Value 129.9m)
FCF Margin = -211.0% (FCF TTM -129.8m / Revenue TTM 61.5m)
Net Margin = -168.2% (Net Income TTM -103.5m / Revenue TTM 61.5m)
Gross Margin = 34.24% ((Revenue TTM 61.5m - Cost of Revenue TTM 40.5m) / Revenue TTM)
Gross Margin QoQ = -2277 % (prev 43.59%)
Tobins Q-Ratio = 0.31 (Enterprise Value 129.9m / Total Assets 412.9m)
Interest Expense / Debt = 8.48% (Interest Expense 4.45m / Debt 52.4m)
Taxrate = -1.50% (negative due to tax credits) (654.0k / -43.5m)
NOPAT = -119.8m (EBIT -118.0m * (1 - -1.50%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 14.08 (Total Current Assets 338.3m / Total Current Liabilities 24.0m)
Debt / Equity = 0.15 (Debt 52.4m / totalStockholderEquity, last quarter 340.7m)
Debt / EBITDA = 0.36 (negative EBITDA) (Net Debt -40.9m / EBITDA -113.8m)
Debt / FCF = 0.31 (negative FCF - burning cash) (Net Debt -40.9m / FCF TTM -129.8m)
Total Stockholder Equity = 391.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -25.06% (Net Income -103.5m / Total Assets 412.9m)
RoE = -26.42% (Net Income TTM -103.5m / Total Stockholder Equity 391.5m)
RoCE = -26.58% (EBIT -118.0m / Capital Employed (Equity 391.5m + L.T.Debt 52.4m))
RoIC = -30.59% (negative operating profit) (NOPAT -119.8m / Invested Capital 391.5m)
WACC = 9.91% (E(404.4m)/V(456.8m) * Re(10.08%) + D(52.4m)/V(456.8m) * Rd(8.48%) * (1-Tc(-0.02)))
Discount Rate = 10.08% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 11.47%
Fair Price DCF = unknown (Cash Flow -129.8m)
EPS Correlation: 18.34 | EPS CAGR: -26.89% | SUE: -0.09 | # QB: 0
Revenue Correlation: 51.97 | Revenue CAGR: 17.92% | SUE: -0.37 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.96 | Chg30d=+0.018 | Revisions Net=+1 | Analysts=4
EPS next Year (2026-12-31): EPS=-4.00 | Chg30d=+0.000 | Revisions Net=+0 | Growth EPS=-18.9% | Growth Revenue=-38.1%

Additional Sources for TRDA Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle